Access
This article is part of Nature's premium content.
Published online 28 November 2007 | Nature 450, 600-601 (2007) | doi:10.1038/450600a
News: Business
Fever pitch
The push for new anti-inflammatory drugs has pharmaceutical companies flocking to a previously abandoned therapy. Heidi Ledford reports on the resurrection of interleukin-1 blockers.
In 1977, researchers isolated a novel protein from human blood that had been exposed to a pathogenic bacterium. Some called the protein a pyrogen because it triggered fever; others called it an activating factor for its ability to stimulate white blood cells.
To read this story in full you will need to login or make a payment (see right).
Comments
Reader comments are usually moderated after posting. If you find something offensive or inappropriate, you can speed this process by clicking 'Report this comment' (or, if that doesn't work for you, email webadmin@nature.com). For more controversial topics, we reserve the right to moderate before comments are published.
There are currently no comments.
